Frank G. Haluska
ARIAD Pharmaceuticals (United States) · 195 works · 28,239 citations · h-index 60
Top works
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
- Analysis of human transcriptomes
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
- Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
- Evolution of B-cell malignancy: pre-B-cell leukemia resulting from MYC activation in a B-cell neoplasm with a rearranged BCL2 gene.
- Genetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma
- Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
- Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
- ONCOGENE ACTIVATION BY CHROMOSOME TRANSLOCATION IN HUMAN MALIGNANCY
- Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities
- Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds
- Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial
- Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
- The t(8; 14) chromosomal translocation occurring in B-cell malignancies results from mistakes in V–D–J joining
- Examination of Mutations in BRAF, NRAS, and PTEN in Primary Cutaneous Melanoma
- Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines